Home Archive
Archive
2024 Volume 45 Issue 10  Published: 2024-10-10
    Topic
  • Gang ZHENG
    doi: 10.13683/j.wph.2024.10.001

    Neurohormonal signaling is one of the main mechanisms of cardiovascular aging, which specifically includes the renin-angiotensin-aldosterone system, β-adrenergic signaling, and insulin-like growth factor-1. Neurohormonal signals are not only involved in cardiovascular failure, but also associated with various cardiovascular diseases such as hypertension, atrial fibrillation, and heart failure, and there may be a common mechanism between the two. This article reviewed the role of neurohormone signaling in cardiovascular aging, aiming to provide reference for the diagnosis, treatment, and new drugs for cardiovascular diseases in the future.

  • Topic
  • Gang ZHENG
    doi: 10.13683/j.wph.2024.10.002

    Mitochondrial dysfunction and cellular aging can accelerate cardiovascular aging through various pathways, leading to the occurrence and development of age-related cardiovascular diseases. Existing evidence suggests that both have the potential to become effective targets for delaying cardiovascular aging. This article reviewed the mechanisms of mitochondrial dysfunction and cellular aging in cardiovascular aging, in order to provide reference for the diagnosis, management and development of therapeutic drugs for cardiovascular diseases in the future.

  • Topic
  • Gang ZHENG
    doi: 10.13683/j.wph.2024.10.003

    Loss of protein homeostasis, genomic instability and inflammation all involve in cardiovascular aging, and which is closely related to the occurrence and development of cardiovascular diseases, such as atherosclerosis, heart failure, cardiomyopathy and other. Therefore, protein homeostasis, genomic stability, and inflammation may be therapeutic targets for age-related cardiovascular diseases. This article reviewed the mechanisms of protein homeostasis loss, genomic instability, and inflammation in cardiovascular aging, in order to provide new directions for the prevention, diagnosis, and development of new drugs for cardiovascular diseases in the future.

  • Article
  • Rong HE , Juan ZHANG , Changhuai ZHOU , Senshan ZHANG , Xu LU
    doi: 10.13683/j.wph.2024.10.004
    Objective

    To investigate the effect of budesonide on pneumonia injury induced by respiratory syncytial virus (RSV) in young mice.

    Methods

    Seventy-two BABL/c young mice were randomly divided into healthy control group, RSV group, low dose group, medium dose group, high dose group and positive control group, with 12 mice in each group. The healthy control group was given 50 μl physiological saline nasal drip, and the other 5 groups were given RSV-long virus for modeling. The healthy control group and RSV group were atomized with the same amount of physiological saline, the low, medium and high dose groups were atomized with 0.2, 0.8 and 1.5 mg/kg budesonide suspension, and the positive control group was atomized with 46 mg/kg ribavirin once a day for 7 days. The pulmonary index, lung wet/dry weight ratio (W/D), lung function and RSV load were compared. Treg/helper T cells (Th17) were detected by flow cytometry. The levels of interleukin (IL)-17, IL-21 and IL-22 were measured by enzyme-linked immunosorbent assay. The nuclear factor (NF)-κB protein was detected by western blotting.

    Results

    Compared with healthy control group, pulmonary index, W/D, RSV load, peak exhalation flow (PEF), resistance inspiratory (RI), resistance exhalation (RE), Th17 proportion, lung tissue and serum IL-17, IL-21, IL-22, NF-κB protein in RSV group increased, dynamic lung compliance (Cdyn), Treg, Treg/Th17 proportion were significantly decreased (P<0.05). Compared with RSV group, pulmonary index, W/D, RSV load, PEF, RI, RE, Th17 proportion, lung tissue and serum IL-17, IL-21, IL-22 and NF-κB protein were decreased in low, medium and high dose groups and positive control group, while Cdyn, Treg and Treg/Th17 proportion were increased (P<0.05).

    Conclusion

    Budesonide can reduce pneumonia injury induced by RSV and improve Treg/Th17 ratio in young mice by regulating NF-κB capacity.

  • Article
  • Lingyun LIU , Hairong YANG , Linxiang PAN , Weixiang ZHU
    doi: 10.13683/j.wph.2024.10.005
    Objective

    To investigate the effect of iguratimod combined with hydroxychloroquine sulfate on erythrocyte sedimentation rate (ESR) and immune imbalance of helper T cell (Th)17/regulatory T cell (Treg) in patients with primary Sjogren's syndrome (pSS).

    Methods

    A total of 199 pSS patients treated in our hospital from January 2019 to December 2023 were selected and divided into experimental group (n=100, hydroxychloroquine sulfate+iguratimod) and control group (n=99, hydroxychloroquine sulfate) by random number table method. Clinical efficacy, ESR, Th17, Treg, salivary flow rate, tear flow rate, tear film breaking time, and EULAR Sjogren's syndrome patient reported index (ESSPRI), EULAR Sjogren's syndrome disease activity index (ESSDAI) and the incidence of adverse reactions were compared between the two groups before and after treatment.

    Results

    After treatment, the total effective rate of experimental group was higher than that of control group (91.00% vs 79.80%, P<0.05). The levels of ESR and Th17 in two groups were significantly lower than before (P<0.05), and those in experimental group were lower than those in control group (P<0.05). The level of Treg in both groups were significantly higher than before (P<0.05), and the experimental group was higher than the control group. The salivary flow rate, tear flow rate and tear film breaking time of the two groups were significantly increased (P<0.05), and the experimental group was higher than the control group (P<0.05). The scores of ESSPRI and ESSDAI in two groups were significantly lower than before (P<0.05), and the experimental group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the experimental group and the control group during treatment (3.00% vs 5.05%, P>0.05).

    Conclusion

    Iguratimod combined with hydroxychloroquine sulfate has better effect on pSS, and can effectively improve the immune imbalance of ESR and Th17/Treg.

  • Article
  • Xiaowen CAO , Lu YE , Shuo FENG , Yuanxiao FAN , Shaokang LI , Jiwei FENG
    doi: 10.13683/j.wph.2024.10.006
    Objective

    To observe the clinical effect of acupuncture combined with Shenqi Dihuang decoction in the treatment of chronic glomerulonephritis (CGN) of Qi and Yin deficiency type.

    Methods

    A total of 96 CGN patients diagnosed in Gongli Hospital of Shanghai Pudong New Area from October 2020 to March 2024 were randomly divided into treatment group and control group, with 48 cases in each group. The control group was treated with basic western medicine, and the treatment group was treated with traditional Chinese medicine combined with acupuncture for 8 weeks. The total effective rate, interleukin (IL)-2, urinary erythrocyte, 24 h urinary protein quantity (24 h UPro), serum creatinine (Scr) and blood urea nitrogen (BUN) levels were compared between the two groups.

    Results

    After treatment, the levels of Scr, 24 h UPro and IL-2 level in the treatment group were all decreased (P<0.05), and the treatment group was lower than the control group (P<0.05). The total effective rate of treatment group was higher than that of control group (83.33% vs 64.58%, P<0.05). There were no obvious adverse reactions in both groups.

    Conclusion

    Acupuncture combined with Shenqi Dihuang decoction is effective and safe in treating CGN of Qi and Yin deficiency type, and the mechanism of action may be related to the regulation of immune factors.

  • Article
  • Xiaofang XIE , Yankong LI , Guang ZHANG , Zesheng LIU , Xin LI
    doi: 10.13683/j.wph.2024.10.007
    Objective

    To investigate the curative effect of modified Shaoyao and Gancao decoction combined with pregabalin in the treatment of malignant neuropathic pain (MNP).

    Methods

    A total of 140 MNP patients admitted to our hospital from September 2022 to September 2023 were randomly divided into western medicine group (pregabalin) and Chinese and western medicine combined group (pregabalin combined with modified Shaoyao Gancao decoction), with 70 cases in each group. The clinical efficacy, pain mediator levels, quality of life and adverse reactions were compared between two groups.

    Results

    The total effective rate of the combined treatment group (91.43%) was higher than that of the western medicine group (75.71%, P<0.05). After treatment, the levels of 5-hydroxytryptamine, Substance P, prostaglandin E2 and endothelin-1 in the combined group were significantly lower than those in the western medicine group (P<0.05). The score of quality of life (QOL) in the combined medicine group was significantly decreased (P<0.05). There was no statistical significance in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Modified Shaoyao Gancao decoction combined with pregabalin can effectively relieve pain in MNP patients, improve clinical efficacy and quality of life, and have good safety.

  • Article
  • Lu ZHANG , Shuzheng LIU , Rui ZHANG , Li'na YANG , Zhuojun LI
    doi: 10.13683/j.wph.2024.10.008
    Objective

    To analyze the efficacy and safety of cefoperazone sulbactam sodium combined with high-dose tigecycline in the treatment of interleukin (IL)-6, procalcitonin (PCT) and other indicators in patients with complicated urinary tract infection.

    Methods

    A total of 156 patients with complicated urinary tract infection caused by carbapenem-resistant Acinetobacter baumannii (CRAB) admitted to the Affiliated Hospital of Tangshan Vocational and Technical College from August 2020 to December 2023 were selected as retrospective study objects. The patients were divided into the high dose group and the routine dose group according to the dose of tigecycline, with 78 cases in each group. The initial dose of tigecycline in the high dose group was 200 mg, and the maintenance dose was 100 mg, twice a day. The initial dose of tigecycline in the routine dose group was 100 mg, and the maintenance dose was 50 mg, twice a day. The clinical efficacy, clinical indexes negative time, the laboratory indexe [IL-6, IL-8, hypersensitive C-reactive protein (hs-CRP) and PCT], the negative rate of urine culture, the incidence of adverse reactions and the oxidative stress indexes [noradrenaline (NE), glutathione peroxidase (GSH-PX), angiotensinogenⅡ (AngⅡ)] and treatment satisfaction were analyzed between the two groups.

    Results

    The total clinical effective rate of the high-dose group was significantly higher than that of the routine dose group (P<0.05). The time of clinical symptoms disappearing, the time of urine white blood cell turning negative, and the time of fever reduction in the high-dose group were significantly shorter than those in the routine dose group (P<0.05). The levels of IL-6, IL-8, hs CRP, and PCT in the high-dose group were significantly lower than those in the routine dose group after treatment (P<0.05). The negative conversion rate of urine culture in the high-dose group was higher than that in the routine dose group (23.36% vs 12.82%, χ2=3.431, P=0.009). The total incidence of adverse reactions in the high-dose group was higher than that in the routine dose group (P>0.05), and the overall treatment satisfaction rate in the high-dose group was higher than that in the routine dose group (96.15% vs 82.05%, P<0.05). The levels of NE, GSH-Px, and AngⅡ in the high-dose group were significantly higher than those in the routine dose group after treatment (P<0.05).

    Conclusions

    High-dose tigecycline combined with cefoperazone-sulbactam sodium has significant efficacy in the treatment of CRAB induced complicated urinary tract infection, and the adverse reactions are not significantly higher than that of the routine dose regimen, and is safe and effective.

  • Article
  • Xingqiang CHEN , Guoliang ZENG , Shaolian CAI
    doi: 10.13683/j.wph.2024.10.009
    Objective

    To investigate the effects of levothyroxine replacement therapy on subclinical hypothyroidism (SCH) after menopause.

    Methods

    A total of 90 postmenopausal SCH patients diagnosed in the First People's Hospital of Zhaoqing from January 2020 to June 2022 were selected as research objects and divided into control group and study group according to simple sort randomization method, with 45 cases in each group. The control group received conventional symptomatic treatment, and the study group received levothyroxine replacement treatment. The clinical effective rate, thyroid function, blood lipid level and the occurrence of adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of the study group was higher than that of the control group (95.56% vs 80.00%, P<0.05). After treatment, there were no significant differences between the two groups in the levels of free triiodothyronine, serum free thyroxine and anti-thyroid peroxidase antibody (P>0.05), but the level of thyroid stimulating hormone (TSH) in the study group was higher than that in the control group (P<0.05). The levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in the study group were lower than those in the control group (P<0.05), and the level of high density lipoprotein cholesterol was higher than that in the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Levothyroxine replacement therapy is an effective and feasible medication regimen for postmenopausal SCH patients, which can help control TSH level, regulate blood lipid, and has good drug safety.

  • Article
  • Lijie WANG , Erjun XU , Xin LYU , Xiaomin SUN , Qimin XU
    doi: 10.13683/j.wph.2024.10.010
    Objective

    To explore the effect of national volume-based procurement (NVBP) policy on the use of anti-tumor drugs in a tertiary A general hospital, and to provide rational advices for improving quantity of drug policies and enhancing hospital pharmaceutical management.

    Methods

    Descriptive statistical methods were used to compare usage quantity, consumption volumes, defined daily dose system (DDDs), defined daily dose cost (DDDc), daily cost ratio and B/A before and after the implementation of NVBP policy of anti-tumor drugs.

    Results

    After the implementation of NVBP policy, the total usage amount of anti-tumor drugs increased from 49 666.35 g to 105 870.91 g, with an increase of 113.16%, the total consumption sum decreased from CNY 13.699 9 million to CNY 4.917 9 million, with a decrease of 64.10%. The DDDc of anti-tumor drugs all showed a decreasing trend, with the daily cost ratio was less than 1.0, a total of 33.814 4 million was saved in expenses, the proportion of usage amount, DDDs, and consumption sum of bid-winning tumor drugs were 100.00%, 99.38%, and 99.30%, respectively.

    Conclusion

    After the implementation of the national volume-based procurement policy in a tertiary comprehensive hospital, the cost of anti-tumor drugs has significantly decreased, which significantly reduces the economic burden on patients, reduces the operating costs of the hospital, and promotes a more reasonable distribution of medical insurance funds.

  • Article
  • Danhua SUN , Li'na DENG , Jingjing HAN , Xiuli JU , Guofang LIU , Wen DONG
    doi: 10.13683/j.wph.2024.10.011
    Objective

    Analyze the clinical efficacy of the combination of denoprorelin suppositories and rivanol for induced labor in scarred uterus.

    Methods

    A total of 98 patients with scarred uterus in the second trimester of pregnancy who were admitted to Port Hospital of Hebei Port Group Co., Ltd. and Changli County Maternal and Child Health Hospital from February 2020 to February 2022 were selected as the research objects. According to the induction protocol, they were divided into the control group (rivanol treatment) and the study group (rivanol+desoprostone suppository treatment), with 49 cases in each group. The perioperative indicators, cervical maturity, success rate of induced labor, adverse reactions and postoperative complications were compared between the two groups.

    Results

    Compared with the control group, the time of uterine contraction initiation, fetal delivery and hospital stay in the study group were significantly shortened (P<0.05). The blood loss during labor induction and 2 h after labor induction in the study group was significantly lower than that in the control group (P<0.05). Bishop score of cervical maturity in study group was higher than that in control group at 6 h, 12 h and 18 h after treatment (P<0.05). The total induced labor rate of the study group (95.92%) was significantly higher than that of the control group (87.76%, P<0.05).

    Conclusion

    Dinoprostione suppository combined with rivanol for inducing labor in scarred uterus of second trimester has good outcome and has clinical promotion potential.

  • Article
  • Yu ZHANG , Yuhan GU , Zhuo WANG , Zhixin ZHENG , Ping ZHU
    doi: 10.13683/j.wph.2024.10.012
    Objective

    To investigate the safety and efficacy of doxycycline in the treatment of lobular pneumonia infected by drug-resistant Mycoplasma pneumoniae (MP) in children.

    Methods

    Children with lobular pneumonia infected by drug-resistant MP admitted to our hospital from July 2023 to April 2024 were selected as the study objects, and their clinical manifestations, etiology detection, laboratory and imaging examination, clinical efficacy and safety were collected and analyzed during hospitalization.

    Results

    Among the 65 patients, there were 34 males and 31 females, of which 28 were ≥8 years old and 37 were <8 years old, with an average age of (7.73±2.41) years. The most common clinical manifestations were cough (65 cases, 100.0%) and fever (64 cases, 98.46%). The right lung was mainly involved in pneumonia (33 cases, 50.77%). The average course of treatment with doxycycline was (7.43±2.95) days, with a dosage of 2 mg/kg every 12 hours. After treatment, the average body temperature of 50 cases (76.92%) dropped to normal within (1.76±1.20) days, 55 cases (84.62%) showed significantly improvement in cough symptoms within (3.58±1.89) days, and 54 cases (83.08%) showed significant absorption in lung imaging, with an average time of (9.00±0.63) days. There was 1 case of rash and 1 case of pain during medication period. After discharge, follow-up was conducted until 3 months after medication, and no drug-related adverse reactions occurred.

    Conclusion

    Doxycycline is safe in the treatment of lobular pneumonia infected by drug-resistant MP in children with proper dose and short course of treatment, and can be appropriately selected in clinical pratice.

  • Article
  • Yuan XU , Jia WANG , Yanhui YANG , Rong LI , Hu YANG , Chunyan SHAN
    doi: 10.13683/j.wph.2024.10.013
    Objective

    To collect the medical records of patients with diabetic kidney disease (DKD) during the course of Shenyan Kangfu tablets, and to analyze the clinical features of Shenyan Kangfu tablets in the treatment of DKD and the improvement of renal function in the real world.

    Methods

    Based on the hospital electronic medical record information system, 503 cases of DKD patients with prescription Shenyan Kangfu tablets from October 1, 2016 to October 31, 2021 were collected to analyze the characteristics of the population taking Shenyan Kangfu tablets in the real world, the distribution of drug diseases, the improvement of renal function, the safety and the combined treatment plan, and to evaluate its efficacy and safety.

    Results

    The age of DKD patients taking Shenyan Kangfu tablets was mainly 30~80 years old, of which 50~60 years old accounted for 33.20% and 60~70 years old accounted for 30.22%. There were more males than females (67.40% vs 32.60%). The results showed that Shenyan Kangfu tablets could significantly reduce urinary protein, urinary albumin/creatinine ratio (ACR), glycosylated hemoglobin (Hb) A1c and other indexes at 24 h. After taking Shenyan Kangfu tablets for 3 months, 24 h urinary protein level increased, hemoglobin, serum albumin, HbA1c levels decreased. During 3 to 6 months, 24 h urinary protein, creatinine and HbA1c levels decreased. After 6 months, ACR levels increased and 24 h urinary protein and HbA1c levels decreased. No adverse reactions were recorded during the administration, and the safety was good. Clinical drug combinations mainly include blood glucose control drugs, blood pressure control drugs, lipid-regulating drugs, etc.

    Conclusion

    There are more DKD patients using Shenyan Kangfu tablet in clinical practice, and the preliminary results show that Shenyan Kangfu tablet combined with conventional western medicine treatment of DKD is safe and effective.

  • Article
  • Bojian WU , Teng HUANG , Jun XIE , Pei LU , Shaozhong PENG , Xiaodan HUANG
    doi: 10.13683/j.wph.2024.10.014
    Objective

    To investigate the clinical efficacy and safety of rheum and pharyngitis oral solution in the treatment of upper respiratory system diseases in children in the real world, and to analyze the correlation between adverse reactions and medication regimen through multi-center retrospective study.

    Methods

    The medical records of 500 children using rheum and pharyngitis oral solution in target centers from May 31, 2016 to May 31, 2022 were collected, and their age, gender, department of treatment, purpose of diagnosis and treatment, drug use, laboratory test results and drug combination information were analyzed.

    Results

    The mean age of the patients was (7.80±3.45) years old. The patients above 6 years old accounted for 56%, followed by the patients between 3 and 6 years old (44.00%). The department with the highest number of patients was pediatrics (57.14%). Acute upper respiratory tract infection (89.20%) was the highest proportion of rheum and pharyngitis oral solution, and Chinese medicine (39.80%) was the highest proportion of rheum and pharyngitis oral solution combined drugs. There were significant differences in single dose, days of medication, total daily dose and total dose of medication cycle between the two age groups (P<0.05). There were no significant differences in blood routine, C-reactive protein and renal function indexes between the first examination and the last examination (P>0.05).

    Conclusion

    At present, rheum and pharyngitis oral solution is mainly used in the adjuvant treatment of upper respiratory system diseases in children, and the efficacy of rheum and pharyngitis oral solution is highly recognized by clinicians.

  • Article
  • Le KANG , Yan WANG , Qi FANG , Mudan HE
    doi: 10.13683/j.wph.2024.10.015
    Objective

    To conduct a meta-analysis of the adverse drug reactions (ADR) caused by crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).

    Methods

    Literature on randomized controlled trials of crizotinib in the treatment of ALK-positive NSCLC published in domestic and foreign databases from the establishment of the database to August 2023 were searched. RevMan 5.4 software was used for meta-analysis.

    Results

    A total of 8 literatures were included, including 2 058 subjects (998 patients in crizotinib test group and 1 060 patients in chemotherapy or other targeted control group), and the quality of the included literatures was good. The overall incidence of ADR (≥grade 3) in test groups was lower than that in control group [RR=0.67, 95% confidence interval (CI): 0.46~0.96, P=0.03]. The incidence of leukopenia, neutrophils and thrombocytopenia (<grade 3) in test group was lower than that in other targeted groups (RR=0.71, 95%CI: 0.55~0.92, P=0.01). The incidence of upper respiratory tract infection (≥grade 3) and liver enzyme elevation (<grade 3) in test group was lower than that in chemotherapy group (RR=0.10, 95%CI: 0.01~0.95, P=0.04; RR=0.84, 95%CI: 0.74~0.94, P=0.004). The incidence of liver enzyme elevation in test group (≥grade 3) was higher than that in chemotherapy group (RR=2.13, 95%CI: 1.14~3.97, P=0.02).

    Conclusion

    Crizotinib has good overall safety and low blood system adverse reactions in the treatment of ALK-positive NSCLC. However, the liver function should be closely monitored to avoid the occurrence of adverse reactions of ≥grade 3 liver enzymes elevation.

  • Review
  • Qing MA , Jianqi JIA , Qian HE
    doi: 10.13683/j.wph.2024.10.016

    Semaglutide was approved by the U.S. Food and Drug Administration on March 8, 2024 for the prevention of cardiovascular disease, heart disease, and cerebral apoplexy in adults who are overweight or obese. Semaglutide improves blood glucose and traditional cardiovascular moderate risk factor levels in obese patients, reduces ectopic adipose tissue that can lead to atherosclerosis and myocardial dysfunction, and improves the systemic pro-inflammatory and pro-thrombotic environment associated with obesity. This article intended to elaborate the mechanism of action, clinical research and safety of semaglutide in the treatment of cardiovascular diseases complicated with obesity from multiple ways and levels, so as to provide certain reference for clinical use.

News